Fractyl Health (NASDAQ:GUTS) Issues Earnings Results

Fractyl Health (NASDAQ:GUTS) posted its earnings results on Tuesday. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.02, Zacks reports. The company had revenue of $0.01 million for the quarter.

Fractyl Health Stock Performance

NASDAQ GUTS traded up $0.04 during trading on Wednesday, reaching $2.47. 247,470 shares of the stock traded hands, compared to its average volume of 317,548. Fractyl Health has a fifty-two week low of $1.74 and a fifty-two week high of $14.50. The company has a quick ratio of 7.46, a current ratio of 7.46 and a debt-to-equity ratio of 0.40. The stock’s 50-day moving average price is $2.65 and its 200 day moving average price is $4.08.

Insiders Place Their Bets

In other Fractyl Health news, insider Jay David Caplan sold 65,000 shares of Fractyl Health stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $2.90, for a total transaction of $188,500.00. Following the transaction, the insider now directly owns 30,484 shares in the company, valued at approximately $88,403.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.